News Minimalist logo

Roche's CT-388 weight loss drug shows promising trial results

CNBC — May 16, 2024, 03:00 PM UTC

Summary: Roche's weight loss drug CT-388 showed promising results in a phase one trial, with patients losing up to 18.8% of their weight. The market for obesity drugs is projected to reach $100 billion by the end of the decade. CT-388 mimics gut hormones to suppress appetite and normalize blood sugar levels. Roche aims to compete with Novo Nordisk and Eli Lilly in the weight loss treatment market.

Full article

Article metrics

The article metrics are deprecated.

I'm replacing the original 8-factor scoring system with a new and improved one. It doesn't use the original factors and gives much better significance scores.

Timeline:

  1. [4.7]
    New therapy targets brain's appetite center for weight loss (News-Medical.Net)
    114d 4h
    Source
  2. [4.4]
    Dual-action drug MK-801 doubles weight loss in mice (Inside Precision Medicine)
    114d 7h
    Source
  3. [2.9]
    New weight loss shot CT-388 shows promising results (Daily Mail)
    114d 7h
    Source
  4. [5.6]
    Wegovy sustains weight loss for at least 4 years (WIRED)
    114d 12h

    ScoresSource
  5. [2.1]
    Novo Nordisk to study Ozempic's effects on alcohol consumption (CNN)
    115d 1h
    Source
  6. [5.5]
    Semaglutides improve heart health by 20% beyond weight loss (The Guardian)
    115d 13h

    ScoresSource
  7. [4.5]
    Personalized semaglutide dosing aids sustainable weight loss (News-Medical.Net)
    116d 5h
    Source
  8. [3.2]
    Ozempic reduces heart attack risk, may help fight other diseases (Daily Mail)
    116d 5h
    Source
  9. [5.2]
    Semaglutide (Ozempic) shows potential for treating addiction and dementia (The Guardian)
    116d 6h

    ScoresSource
  10. [3.0]
    New weight loss jab retatrutide shows promising results (Daily Mail)
    116d 7h
    Source
  11. [3.1]
    "Book 'Magic Pill' delves into weight loss drug Ozempic." (Mint)
    116d 10h
    Source
  12. [5.8]
    Semaglutide reduces heart attack risk by 20% (Irish Examiner)
    116d 12h

    ScoresSource
  13. [5.8]
    Semaglutide reduces heart attack risk by 20% (The Guardian)
    116d 23h

    ScoresSource
  14. [4.2]
    Wegovy trial shows 10% weight loss maintained after 4 years (CTV News)
    116d 23h
    Source
  15. [5.1]
    Wegovy's long trial shows sustained 10% weight loss, heart protection (CNN)
    117d 0h

    ScoresSource
  16. [4.6]
    Semaglutide reduces need for diuretics in heart failure patients (Diagnostic and Interventional Cardiology)
    117d 6h
    Source
  17. [3.9]
    Semaglutide improves heart failure symptoms and reduces diuretic dose (News-Medical.Net)
    117d 6h
    Source
  18. [4.5]
    Author suggests India learn from Japan's diet success, caution on weight-loss drugs (BusinessLine)
    117d 19h
    Source
  19. [2.2]
    1 in 8 US adults use GLP-1 drugs like Ozempic (CNN)
    120d 12h
    Source
  20. [3.1]
    Wegovy weight loss drug now available in Canada (CTV News Kitchener)
    122d 2h
    Source